Advertisement

Resolving Liquid-Liquid Phase Separation for a Peptide Fused Monoclonal Antibody by Formulation Optimization

Published:September 18, 2020DOI:https://doi.org/10.1016/j.xphs.2020.09.020

      Abstract

      Liquid-liquid phase separation (LLPS) of protein solutions has been usually related to strong protein-protein interactions (PPI) under certain conditions. For the first time, we observed the LLPS phenomenon for a novel protein modality, peptide-fused monoclonal antibody (pmAb). LLPS emerged within hours between pH 6.0 to 7.0 and disappeared when solution pH values decreased to pH 5.0 or lower. Negative values of interaction parameter (kD) and close to zero values of zeta potential (ζ) were correlated to LLPS appearance. However, between pH 6.0 to 7.0, a strong electrostatic repulsion force was expected to potentially avoid LLPS based on the sequence predicted pI value, 8.35. Surprisingly, this is significantly away from experimentally determined pI, 6.25, which readily attributes the LLPS appearances of pmAb to the attenuated electrostatic repulsion force. Such discrepancy between experiment and prediction reminds the necessity of actual measurement for a complicated modality like pmAb. Furthermore, significant protein degradation took place upon thermal stress at pH 5.0 or lower. Therefore, the effects of pH and selected excipients on the thermal stability of pmAb were further assessed. A formulation consisting of arginine at pH 6.5 successfully prevented the appearance of LLPS and enhanced its thermal stability at 40 °C for pmAb. In conclusion, we have reported LLPS for a pmAb and successfully resolved the issue by optimizing formulation with aids from PPI characterization.

      Keywords

      To read this article in full you will need to make a payment
      APhA Member Login
      APhA Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kheddo P.
        • Bramham J.E.
        • Dearman R.J.
        • Uddin S.
        • van der Walle C.F.
        • Golovanov A.P.
        Investigating liquid-liquid phase separation of a monoclonal antibody using solution-state NMR spectroscopy: effect of Arg.Glu and Arg.HCl.
        Mol Pharm. 2017; 14: 2852-2860
        • Raut A.S.
        • Kalonia D.S.
        Pharmaceutical perspective on opalescence and liquid-liquid phase separation in protein solutions.
        Mol Pharm. 2016; 13: 1431-1444
        • Salinas B.A.
        • Sathish H.A.
        • Bishop S.M.
        • Harn N.
        • Carpenter J.F.
        • Randolph T.W.
        Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation.
        J Pharm Sci. 2010; 99: 82-93
        • Oki S.
        • Nishinami S.
        • Shiraki K.
        Arginine suppresses opalescence and liquid-liquid phase separation in IgG solutions.
        Int J Biol Macromol. 2018; 118: 1708-1712
        • Shire S.J.
        • Shahrokh Z.
        • Liu J.
        Challenges in the development of high protein concentration formulations.
        J Pharm Sci. 2004; 93: 1390-1402
        • Taratuta V.G.
        • Holschbach A.
        • Thurston G.M.
        • Blankschtein D.
        • Benedek G.B.
        Liquid-liquid phase separation of aqueous lysozyme solutions: effects of pH and salt identity.
        J Phys Chem. 1990; 94: 2140-2144
        • Chinchalikar A.J.
        • Aswal V.K.
        • Kohlbrecher J.
        • Wagh A.G.
        Small-angle neutron scattering study of structure and interaction during salt-induced liquid-liquid phase transition in protein solutions.
        Phys Rev. 2013; 87: 62708
        • Liu C.
        • Asherie N.
        • Lomakin A.
        • Pande J.
        • Ogun O.
        • Benedek G.B.
        Phase separation in aqueous solutions of lens gamma-crystallins: special role of gamma s.
        Proc Natl Acad Sci U S A. 1996; 93: 377-382
        • Thomson J.A.
        • Schurtenberger P.
        • Thurston G.M.
        • Benedek G.B.
        Binary liquid phase separation and critical phenomena in a protein/water solution.
        Proc Natl Acad Sci U S A. 1987; 84: 7079
        • Mason B.D.
        • Zhang-van Enk J.
        • Zhang L.
        • Remmele R.L.
        • Zhang J.
        Liquid-liquid phase separation of a monoclonal antibody and nonmonotonic influence of hofmeister anions.
        Biophys J. 2010; 99: 3792-3800
        • Ahamed T.
        • Esteban B.N.A.
        • Ottens M.
        • et al.
        Phase behavior of an intact monoclonal antibody.
        Biophys J. 2007; 93: 610-619
        • Wang Y.
        • Lomakin A.
        • Latypov R.F.
        • et al.
        Phase transitions in human IgG solutions.
        J Chem Phys. 2013; 139: 121904
        • Wu G.
        • Wang S.
        • Tian Z.
        • et al.
        Elucidating the weak protein-protein interaction mechanisms behind the liquid-liquid phase separation of a mAb solution by different types of additives.
        Eur J Pharm Biopharm. 2017; 120: 1-8
        • Kamerzell T.J.
        • Esfandiary R.
        • Joshi S.B.
        • Middaugh C.R.
        • Volkin D.B.
        Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development.
        Adv Drug Deliv Rev. 2011; 63: 1118-1159
        • Mason B.D.
        • Zhang L.
        • Remmele R.L.
        • Zhang J.
        Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid–liquid phase separation.
        J Pharm Sci. 2011; 100: 4587-4596
        • Trilisky E.
        • Gillespie R.
        • Osslund T.D.
        • Vunnum S.
        Crystallization and liquid-liquid phase separation of monoclonal antibodies and fc-fusion proteins: screening results.
        Biotechnol Prog. 2011; 27: 1054-1067
        • Zhang L.
        • Yu L.
        • Zhang-Van Enk J.
        • Huang G.
        • Zhang J.
        Phase behavior of an fc-fusion protein reveals generic patterns of ion-specific perturbation on protein-protein interactions.
        J Pharm Sci. 2017; 106: 3287-3292
        • Raut A.S.
        • Kalonia D.S.
        Liquid-liquid phase separation in a dual variable domain immunoglobulin protein solution: effect of formulation factors and protein-protein interactions.
        Mol Pharm. 2015; 12: 3261-3271
        • Raut A.S.
        • Kalonia D.S.
        Effect of excipients on liquid-liquid phase separation and aggregation in dual variable domain immunoglobulin protein solutions.
        Mol Pharm. 2016; 13: 774-783
        • Reiche K.
        • Hartl J.
        • Blume A.
        • Garidel P.
        Liquid-liquid phase separation of a monoclonal antibody at low ionic strength: influence of anion charge and concentration.
        Biophys Chem. 2017; 220: 7-19
        • Nishi H.
        • Miyajima M.
        • Wakiyama N.
        • et al.
        Fc domain mediated self-association of an IgG1 monoclonal antibody under a low ionic strength condition.
        J Biosci Bioeng. 2011; 112: 326-332
        • Zhang F.
        • Roth R.
        • Wolf M.
        • et al.
        Charge-controlled metastable liquid–liquid phase separation in protein solutions as a universal pathway towards crystallization.
        Soft Matter. 2012; 8: 1313-1316
        • Du Q.
        • Damschroder M.
        • Pabst T.M.
        • Hunter A.K.
        • Wang W.K.
        • Luo H.
        Process optimization and protein engineering mitigated manufacturing challenges of a monoclonal antibody with liquid-liquid phase separation issue by disrupting inter-molecule electrostatic interactions.
        mAbs. 2019; 11: 789-802
        • Kamerzell T.J.
        • Esfandiary R.
        • Joshi S.B.
        • Middaugh C.R.
        • Volkin D.B.
        Protein–excipient interactions: mechanisms and biophysical characterization applied to protein formulation development.
        Adv Drug Deliv Rev. 2011; 63: 1118-1159
        • Ferreira G.M.
        • Calero-Rubio C.
        • Sathish H.A.
        • Remmele Jr., R.L.
        • Roberts C.J.
        Electrostatically mediated protein-protein interactions for monoclonal antibodies: a combined experimental and coarse-grained molecular modeling approach.
        J Pharm Sci. 2019; 108: 120-132
        • Filoti D.I.
        • Shire S.J.
        • Yadav S.
        • Laue T.M.
        Comparative study of analytical techniques for determining protein charge.
        J Pharm Sci. 2015; 104: 2123-2131
        • Woldeyes M.A.
        • Qi W.
        • Razinkov V.I.
        • Furst E.M.
        • Roberts C.J.
        How well do low- and high-concentration protein interactions predict solution viscosities of monoclonal antibodies?.
        J Pharm Sci. 2019; 108: 142-154
        • Yang D.
        • Kroe-Barrett R.
        • Singh S.
        • Laue T.
        IgG charge: practical and biological implications.
        Antibodies. 2019; 8: 24
        • Miyatake T.
        • Yoshizawa S.
        • Arakawa T.
        • Shiraki K.
        Charge state of arginine as an additive on heat-induced protein aggregation.
        Int J Biol Macromol. 2016; 87: 563-569
        • Schneider C.P.
        • Shukla D.
        • Trout B.L.
        Arginine and the hofmeister series: the role of ion–ion interactions in protein aggregation suppression.
        J Phys Chem B. 2011; 115: 7447-7458
        • Fukuda M.
        • Kameoka D.
        • Torizawa T.
        • et al.
        Thermodynamic and fluorescence analyses to determine mechanisms of IgG1 stabilization and destabilization by arginine.
        Pharm Res. 2014; 31: 992-1001
        • Inoue N.
        • Takai E.
        • Arakawa T.
        • Shiraki K.
        Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations.
        Mol Pharm. 2014; 11: 1889-1896
        • Arakawa T.
        • Ejima D.
        • Tsumoto K.
        • et al.
        Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects.
        Biophys Chem. 2007; 127: 1-8
        • Yoshizawa S.
        • Arakawa T.
        • Shiraki K.
        Thermal aggregation of human immunoglobulin G in arginine solutions: contrasting effects of stabilizers and destabilizers.
        Int J Biol Macromol. 2017; 104: 650-655
        • Hong T.
        • Iwashita K.
        • Shiraki K.
        Viscosity control of protein solution by small solutes: a review.
        Curr Protein Pept Sci. 2018; 19: 746-758
        • Kim N.A.
        • Hada S.
        • Thapa R.
        • Jeong S.H.
        Arginine as a protein stabilizer and destabilizer in liquid formulations.
        Int J Pharm. 2016; 513: 26-37